Use este identificador para citar ou linkar para este item:
http://www.repositorio.ufop.br/jspui/handle/123456789/17532
Título: | Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats. |
Autor(es): | Gomes, Fabiana Aparecida Rodrigues Noronha, Sylvana Izaura Salyba Rendeiro de Noronha Silva, Sabrina Carla Alves e Machado Júnior, Pedro Alves Ostolin, Thais Lopes Valentim Di Paschoale Chírico, Máira Tereza Talma Ribeiro, Marcelo C. Reis, Alexandre Barbosa Cangussú, Silvia Dantas Montano, Nicola Silva, Valdo Jose Dias da Menezes, Rodrigo Cunha Alvim de Silva, Fernanda Cacilda dos Santos Chianca Júnior, Deoclécio Alves |
Palavras-chave: | Ivabradine HCN channels Blood pressure Hypertension Renal and cardiac inflammatory response |
Data do documento: | 2022 |
Referência: | GOMES, F. A. R. et al. Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats. Life Sciences, v. 308, artigo 120919, 2022. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0024320522006191>. Acesso em: 01 ago. 2023. |
Resumo: | Hypertension is linked to hyperpolarization-activated cyclic nucleotide-gated (HCN) function, expressed in excitable and non-excitable cells. Considering that the reduction in heart rate (HR) improves coronary perfusion and cardiac performance, ivabradine (IVA) emerged as an important drug for the treatment of cardiovascular diseases. Aim: Evaluate if IVA chronic treatment effect can mitigate hypertension and reverse the cardiac and renal damage in SHR. Main methods: Rats were divided into 4 groups treated for 14 days with PBS (1 ml/kg; i.p) or IVA (1 mg/kg; i.p): 1) WKY PBS; 2) SHR PBS; 3) WKY IVA; and 4) SHR IVA. The systolic blood pressure (SBP) was measured, indirectly, before and during the treatment period with IVA (day 0, 1, 7 and 11). Rats were subjected to artery cannulation for direct blood pressure (BP) measurement. Morphofunctional and gene expression were evaluated in the heart and kidneys. Key findings: IVA reduced SBP only in SHR on the 7th day. Direct blood pressure measurement showed that IVA chronic treatment reduced HR in the SHR. Interestingly, mean arterial pressure (MAP) was reduced in SHR IVA when compared to SHR PBS. Serum and urinary biochemical data were not altered by IVA. Moreover, IVA reduced the renal inflammatory infiltrates and increased glomerular density, besides preventing the cardiac inflammatory and hypertrophic responses. Significance: IVA treatment lowered blood pressure, improved cardiac remodeling and inflammation, as well as decreasing renal damage in SHR. Further, IVA increased renal HCN2 mRNA and reduced cardiac HCN4 mRNA. |
URI: | http://www.repositorio.ufop.br/jspui/handle/123456789/17532 |
Link para o artigo: | https://www.sciencedirect.com/science/article/pii/S0024320522006191 |
DOI: | https://doi.org/10.1016/j.lfs.2022.120919 |
ISSN: | 0024-3205 |
Aparece nas coleções: | DEACL - Artigos publicados em periódicos |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
ARTIGO_IvabradineTreatmentLowers.pdf Restricted Access | 3,59 MB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.